Webinar: Cardiovascular event adjudication during COVID-19 and beyond
51:39
Description
Related Videos
View More
View Less
51:39
57:01
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
58:34
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
1:01:11